A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic SyndromeAndrew H. Wei, Meagan A. Jacoby, Jacqueline S. Garcia et al.|Blood|2019Cited by 46
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Danilo Perrotti, Rossana Trotta et al.|Blood Cancer Discovery|2020Cited by 34
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal responseNaveen Pemmaraju, Jacqueline S. Garcia, Rosa Ayala et al.|Blood Neoplasia|2024Cited by 12